Acadian Asset Management
SGTX

Acadian Asset Management’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Acadian Asset Management’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-854
Closed -$30K – 1867
2021
Q4 		$30K Buy
+854
New +$48.6K ﹤0.01% 1562

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management's SGTX Position: Q1 2022 in Review

Acadian Asset Management sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q1 2022, closing a stake of 854 shares — an estimated $30K sold.

Acadian Asset Management first reported a position in SGTX in Q4 2021 and held it in 1 quarter. The position peaked at $30K in Q4 2021. 48 funds tracked by Wall St. Rank hold SGTX as of Q1 2022.

  • Acadian Asset Management reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Acadian Asset Management sold 854 Sigilon Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $30K.
  • Acadian Asset Management first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Acadian Asset Management's Sigilon Therapeutics, Inc. Common Stock position peaked at $30K in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Acadian Asset Management's 13F filing for Q1 2022, filed 12 May 2022.